Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 913-923

  Bras Goncalves R A ^a   Rosty, C ^b   Laurent Puig, P ^b   Soulie P ^a   Dutrillaux, B ^a   Poupon, M F ^a  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

Author keywords

CPT 11; Human colorectal cancer; MSI; Nude mice; p53; top1

Indexed keywords

ALANINE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; MICROSATELLITE DNA; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 0033973828     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1019     Document Type: Article

References (63)

1. Armand JP, Ducreux M, Mahjouhi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287
2. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M and Clavel M (1996) Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 7: 837-842
3. Arnheim N and Shibata D (1997) DNA mismatch repair in mammals: role in disease and meiosis. Curr Opin Gen Dev 7: 364-370
4. Attalla H, Makela TP, Wahala K, Rasku S, Andersson LC and Adlercreutz H (1997) 2,6-Bis((3,4-dihydroxyphenyl)-methylene)cyclohexanone (BDHPC)-induced apoptosis and p53-independent growth inhibition: synergism with genistein. Biochem Biophys Res Commun 239: 467-472
5. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12: 2641-2649
6. Casares S, Ionov Y, Ge HY, Stanbridge E and Perucho M (1995) The microsatellite mutator phenotype of colon cancer cells is often recessive. Oncogene 11: 2303-2310
7. Ceraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, Orvain C, Frebourg T, Klein-Soyer C and Bergerat JP (1998) Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 75: 432-438
8. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S and Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715
9. Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G and Hamelin R (1996) Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 13: 2727-2730
10. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815
11. dos Santos NR, Seruca R, Constancia M, Seixas M and Sobrinho-Simoes M (1996) Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 110: 38-44
12. el-Mahdani N, Vaillant JC, Guiguet M, Prevut S, Bertrand V, Bernard C, Parc R, Bereziat G and Hermelin B (1997) Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer 75: 528-536
13. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Jr, Magrath I, Kohn KW and O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830
14. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291
15. Goh HS, Yao J and Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221
16. Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Maillard JA, Wiesenfeld M, Schaefer PL, Tirona MT and Moertel CG (1997) Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the 1-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15: 3320-3329
17. Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y (1995) Topoisomerase 1-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121
18. Gottesman MM, Pastan I and Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617
19. Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD (1998) An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 95: 5166-5171
20. Hamelin R, Jego N, Laurent-Puig P, Vidaud M and Thomas G (1993) Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8: 2213-2220
21. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G (1994) Association of p53 mutations with short survival in colorectal cancer [see comments]. Gastroenterology 106: 42-48
22. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R (1997) BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 57: 300-303
23. Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice hearing xenografts of human tumors. Cancer Chemoth Pharm 36: 393-403
24. Ishimaru G, Adachi J, Shiseki M, Yamaguchi N, Muto T and Yokota J (1995) Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer 64: 153-157
25. Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM and Boven E (1998) CPT-11 sensitivity in relalion to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 77: 359-365
26. Kaneda N, Nagata H, Furuta T and Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720
27. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
28. Kjeldsen E, Svejstrup JQ, Gromma H, Alsner J and Westergaard O (1992) Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J Mol Biol 228: 1025-1030
29. Köhler T, Lassner D, Rost A-K, Thamm B, Pustowoit B and Remke H (1995) Quantitation of mRNA by Polymerase Chain Reaction, Non-radioactive PCR Methods. Springer-Verlag: Berlin
30. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947
31. Laurence J, Mitra D, Steiner M, Lynch D, Siegal F and Staiano-Coico L (1996) Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. Am Soc Clin Invest 97: 672-680
32. Leteurtre F, Fesen M, Kohlhagen G, Kohn KW and Pommier Y (1993) Specific interaction of camptothecin, a topoisomerase 1 inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 32: 8955-8962
33. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
34. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
35. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I and Hamilton SR (1998) Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227: 51-56
36. McDonald AC and Brown R (1998) Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer 78: 745-751
37. Malkhosyan S, McCarty A, Sawai H and Perucho M (1996) Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the microsatellite mutator phenotype. Mutat Res 316: 249-259
38. Meterissian SH, Kontogiannea M, Po J, Jensen G and Ferdinand B (1997) Apoptosis induced in human colorectal carcinoma by anti-Fas antibody. Ann Surg Oncol 4: 169-175
39. Micheau O, Solary E, Hammann A, Martin F and Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer 189: 783-789
40. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH and et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [see comments]. N Engl J Med 322: 352-358
41. Murphy LD, Herzog CE, Rudick JB, Fojo AT and Bates SE (1990) Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29: 10351-10356
42. Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ and Thomas G (1997) Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 94: 12122-12127
43. Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL and Winn R (1997) Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15: 2905-2909
44. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B and Remvikos Y (1996) Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12: 875-882
45. Pommier Y (1996) Eukaryotic DNA topoisomerase 1: genome gatekeeper and its intruders, camptothecins. Semin Oncol 23: 3-10
46. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commereon A, Pond SM and Robert J (1996) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56: 3689-3694
47. Rothenberg ML (1997) Topoisomerase 1 inhibitors: review and update. Ann Oncol 8: 837-855
48. Rougier P and Bugat R (1996) CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23: 34-41
49. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P and Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260
50. Shao RG, Cao CX, Nieves-Neira W, Pilon AA and Strumberg D (1998) Camptothecin induced apoptosis in human colon carcinoma p53 mutant HT29 cells: role of apocrine signaling through Fas and cytokine pathways. Proc Am Assoc Cancer Res 39: 178
51. Soulie P, Poupon MF, Remvikos Y, Dutrillaux B and Muleris M (1999) Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers. Oncogene 18: 775-781
52. Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH and Moller P (1997) CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 113: 160-167
53. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E and et al (1995) Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. JPN J Cancer Res 86: 978-984
54. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757
55. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y (1994) Comparison of topoisomerase 1 inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer 186: 836-842
56. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F and Pommier Y (1995) Differential stabilization of eukaryotic DNA topoisomerase 1 cleavable complexes by camptothecin derivatives. Biochemistry 34: 7200-7206
57. Tillman DM, Harwood FG, Gibson AA and Houghton JA (1998) Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Differentiation 5: 450-457
58. Vamvakas S, Vock EH and Lutz WK (1997) On the role of DNA double-strand breaks in toxicity and carcinogenesis. Crit Rev Toxicol 27: 155-174
59. van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, Boven E and Giaccone G (1998) Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Brit J Cancer 77: 2171-2176
60. Vaurs C and Bignon YJ (1997) What's new about microsatellite instability significance in human carcinogenesis? Bull Cancer 84: 1061-1071
61. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT and Slim GA (1966) J Am Chem Soc 88: 3888-3890
62. Wilke H (1996) Semin Oncol 23: 1-2
63. Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, Sobrinho-Simoes M, Lothe RA, Gleeson CM, Russell SE, Muzeau F, Flejou JF, Hoang-Xuan K, Lidereau R, Thomas G and Hamelin R (1998) Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 21: 101-107